Our bioinformatics data suggest that LUAD patients with low DUSP22 expression had a worse prognosis, which may be potentially associated with increased EGFR/c-Met signaling, leading to further activation of downstream signaling and driving lung cancer cell growth, migration/invasion, and PD-L1 upregulation. Here, MET is linked to lung carcinoma.